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Abstract 
Antiphospholipid syndrome (APS) is an autoimmune condition characterized by the occurrence of thrombosis 
(arterial and/or venous), often multiple, and/or pregnancy morbidity. Thrombosis is one of the major disease 
mechanisms, mainly caused by activating endothelial cells, monocytes, and platelets. At present, the management of 
APS patients with a history of thrombosis is based on long-term antithrombotic therapy, due to the high rate of 
recurrent thrombosis (29% per year without treatment). Obstetrical APS includes heterogeneous pregnancy 
complications whose pathogenesis has been increasingly elucidated in the past years. This is due to the current 
management and treatment, as 80% of APS patients achieve a live birth. The standard approach of APS is not 
supported by extensive evidence and the best options for refractory and incomplete cases need to be clarified. New 
and promising molecules are under investigation. 
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Introduction 
Antiphospholipid syndrome (APS) is an autoimmune condition characterized by the occurrence of 
thrombosis (arterial and/or venous), often multiple, and/or morbidity in pregnancy (recurrent 
miscarriages, fetal deaths (FDs), and late pregnancy complications such as preeclampsia (PreE) and 
intrauterine growth restriction (IUGR)), in the presence of antiphospholipid antibodies (aPLs), 
typically the antibodies included in the classification criteria for APS, lupus anticoagulant (LA), 
anticardiolipin (aCL), or anti-β2 glycoprotein-I (anti-β2GPI) antibodies (Table 1), although other 
“non-criteria” antibodies may also play a role. APS may be associated with other autoimmune 
diseases, mainly systemic lupus erythematosus (SLE), but it can also be seen in patients having no 
other definable rheumatologic condition (primary APS). Occasionally, it can accompany other 
conditions, such as infections, drugs, or malignancies [1]. 
 
In this review, we discuss recent advances in the diagnosis of APS including new insights into the 
pathogenesis and the implications for the identification of new biomarkers. In addition, the importance 
of recent longitudinal observational studies in understanding the natural history of the syndrome and 
for embedding research in clinical practice will be elucidated. 
Thrombotic APS 
Pathogenesis 
Although the full pathogenesis of APS is not yet clear, the key mechanisms have been described 
recently. Thrombosis is one of the major disease features, driven by multiple mechanisms including 
activation of endothelial cells, monocytes, platelets, coagulation, and complement pathways in 
addition to inhibition of fibrinolytic and anticoagulation pathways [2]. Recent evidence indicates that 
vasculopathy, enhanced mainly by severe intimal hyperplasia, can also play a role in arterial vascular 
occlusion (due to stenotic lesions) and pregnancy morbidity [3]. In support of this hypothesis, Canaud 
et al. [3] recently demonstrated that the vascular endothelium of proliferating intrarenal vessels from 
patients with APS nephropathy showed indications of activation of the mammalian target of rapamycin 
(mTOR) pathway. In cultured vascular endothelial cells, IgG antibodies in patients with APS 
stimulated mTOR through the phosphatidylinositol 3-kinase (PI3K)-AKT pathway. Patients with APS 
nephropathy who required renal transplantation and were treated with sirolimus (also known as 
rapamycin, which can inhibit mTOR) showed no recurrence of vascular lesions and decreased vascular 
proliferation on biopsy compared with patients with aPLs who were not treated with sirolimus. Of 10 
patients treated with sirolimus, seven (70%) had a functioning renal allograft 144 months after 
transplantation versus three of 27 untreated patients (11%). This study conducted in patients with 
primary and secondary APS nephropathy, which is mainly mediated by vasculopathy rather than 
thrombosis, revealed that the activation of the mTOR enzyme stimulates intimal hyperplasia, leading 
to the formation of the chronic vascular lesions seen in APS. Confirmatory studies and more detailed 
investigation of the steps leading to mTOR pathway recruitment and the molecular consequences of its 
activation are still needed. However, there is growing evidence that these enzymes can also induce a 
prothrombogenic phenotype leading to thrombosis [4]. This might represent an obstacle in proceeding 
further to test drugs such as sirolimus in patients with APS [4]. 
Diagnosis and thrombotic risk assessment 
aPL profile and thrombotic risk assessment 
The relationship between aPLs and thrombosis has been widely investigated, and a strong association 
between aPLs and thrombotic events has been confirmed [5]. However, the strength of these results 
from clinical studies is limited by factors such as differences in the study design and eligibility criteria, 
and by the diversity of aPLs in terms of types, isotypes, cutoff, and laboratory methods used for their 
detection. 
In clinical practice, it is common to question whether patients with similar clinical manifestations but 
different patterns and/or combinations of positive aPL test results should be considered equivalent. 
Patients may have single, double, or triple aPL positivity; have single or multiple isotypes of aCL and 
anti-β2GPI; or show low versus high titers of antibodies. Whether heterogeneity of “aPL profiles” 
represents a spectrum of different categories in terms of prognosis and treatment is still a matter of 
debate. 
Recent studies [6] and [7] suggest that multiple positive tests for aPLs are more frequently associated 
with thromboembolic events than a single positive test. However, the presence of a single positive test 
still has to be considered when assessing thrombotic risk, especially in the context of concomitant 
autoimmune disease or other cardiovascular risk factors [8]. 
Available studies suggest that LA is the single aPL most strongly related to thrombosis [5]. Data from 
a systematic review of >7000 patients and controls from 25 studies showed that LA has an odds ratio 
(OR) for thrombosis 5–16 times higher than controls. By contrast, isolated positivity for other aPLs 
was weakly associated with clinical manifestations of APS[9] and [10]. Although LA positivity 
increased the risk of stroke 48-fold and the risk of myocardial infarction 11-fold, anti-β2GPI only 
doubled the risk of stroke, with no effect on myocardial infarction [10]. The role of aCL in the absence 
of LA was also analyzed, and no associated increased risk for stroke or myocardial infarction was 
reported [10]. 
By contrast, some observational studies suggest that patients with SLE and isolated medium–high titer, 
and persistently positive aCL (defined as more than two-third of positive serial determinations), had an 
increased risk of thrombosis, while those with occasional aCL positivity did not [11]. 
Combined aPL positivity has been associated with an increased thrombotic risk [6]. The so-called 
triple-positive population (LA + aCL + anti-β2GPI) has been postulated to be the highest risk 
group [7]. Recently, our group evaluated several combinations of aPL specificities in an attempt to 
determine the profile that provides the best diagnostic accuracy, not only for APS as a whole but also 
for thrombosis and pregnancy morbidity independently [12]. Testing for six aPLs resulted in 23 
possible combinations. The profile of LA + anti-β2GPI + anti-phosphatidylserine–prothrombin, 
aPS/PT, had the best diagnostic accuracy for APS as a whole and individually for both thrombosis 
and/or pregnancy loss (OR 3.73 (95% confidence interval (CI) 1.82–5.38) and OR 3.75 (95% CI 2.13–
6.62), and/or OR 4.82 (95% CI 2.17–10.72), respectively), and the best specificity when compared 
with all the other possible combinations [12]. Multiple aPL positivity also seems to play a role in terms 
of antibody persistence, and individuals testing positive for more than one aPL tend to have more 
stable antibody levels on repeated determinations[13]. 
In a pediatric population, a statistically significant association between first thromboembolism and 
persistently positive aPLs, with an overall sixfold increase in the risk for thrombosis, was also 
reported. These data suggest that the detection of persistent aPLs is clinically meaningful in children 
with, or at risk of, thromboembolism [14]. 
The clinical value of different aPL profiles when assessing the risk of recurrence is also a matter of 
debate. A recent meta-analysis by Garcia et al. [15] showed that patients with first venous 
thromboembolism (VTE) who have aPLs have a higher risk of recurrent VTE when compared with 
patients without aPLs [15]. However, testing for aPLs varied with respect to the antibody sought (aCL, 
anti-β2GPI, and/or LA), with some studies testing for one aPL, and others testing for more than one, 
limiting the conclusions drawn. 
The aPL risk categories according to profile are shown in Table 2. 
Non-criteria aPLs 
It has been proposed that several autoantibodies besides aCL, LA, and anti-β2GPI are relevant to APS. 
These antibodies are directed against other plasma proteins from the coagulation cascade (i.e., PT 
and/or PS–PT complexes), to specific domains of β2GPI, or interfere with the anticoagulant activity of 
annexin A5 (A5) [16]. The clinical utility of these newly developed assays and their clinical value in 
assessing thrombotic risk are being investigated. 
IgA isotypes 
The issue of the value of immunoglobulin A (IgA) aPL and whether it should be part of the routine 
diagnostic algorithm has been a subject of intense debate. The current laboratory criteria for APS omit 
the use of IgA isotypes for both aCL and anti-β2GPI tests. Some available data support testing for IgA 
aPLs. As data are based on retrospective studies, case reports, and case series, clear-cut 
recommendations are difficult to make. In addition, comparison between these studies is difficult due 
to differences in design, population studied, the non-standardized assays used, and the different cutoff 
chosen for the definition of positivity. As a result and in the absence of well-designed prospective 
studies, the usefulness of IgA aPL testing in assessing the thrombotic risk in APS continues to be 
debatable. 
Several studies failed to prove the usefulness of IgA aCL and IgA anti-β2GPI testing, because of low 
prevalence of these antibodies, because they are found along with other aPLs in most cases, and, 
mainly, because of failure to enhance the diagnostic accuracy of routine testing [17]. Recent 
studies [18] suggested that isolated IgA anti-β2GPI may identify additional patients with clinical 
features of APS, and hence recommended testing for these antibodies when other aPLs are negative 
and APS is suspected. It is important to note that of the 5892 samples tested in this study, only 57 
(<1%) were exclusively positive for IgA anti-β2GPI, restricting the application of these 
recommendations to a limited population of patients. 
Based on the published evidence, IgA aPL testing should only be considered for thrombotic risk 
assessment in selected cases, in the presence of clinical signs and symptoms of APS, mainly associated 
with SLE, and, particularly, when other aPL tests are negative [19]. 
Antiprothrombin antibodies 
Antiprothrombin antibodies have been proposed as potential new biomarkers for thrombosis and/or 
pregnancy morbidity in the setting of APS. Antiprothrombin antibodies are commonly detected by 
enzyme-linked immunosorbent assay (ELISA), using prothrombin coated onto irradiated plates (aPT), 
or prothrombin in complex with phosphatidylserine (aPS/PT), as antigen. Although these antibodies 
can coexist in the same patient, aPT and aPS/PT seem to belong to different populations of 
autoantibodies[20]. 
The clinical value of antiprothrombin antibodies, detected as either aPT or aPS/PT, has been evaluated 
with contradictory results [21] and [22]. Most of the studies support an association between antibodies 
directed to prothrombin, particularly aPS/PT, and clinical manifestations of APS. A recent systematic 
review based on data from >7000 patients and controls suggests that while both aPT and aPS/PT 
increased the risk of thrombosis, aPS/PT seems to represent a stronger risk factor for both arterial 
and/or venous thrombosis than aPT [23]. The possibility of antiprothrombin antibodies, particularly 
aPS/PT, being an additional tool for risk stratification is being actively debated, especially when trying 
to improve the identification of APS patients negative for the criteria aPLs. 
Autoantibodies to domain 1 of β2GPI 
Several studies have investigated the epitope distribution of anti-β2GPI antibodies with the aim of 
identifying the pathogenic specificities [24] and [25]. The β2GPI molecule has five homologous 
domains (D): D1–D5. Most of the antibodies have been reported to bind to epitopes located in the 
domains β2GPI-D1, D4, and D5 and these antibodies may have different clinical interpretations [26]. 
The main epitope associated with APS has been reported to be cryptic and a conformation-dependent 
structure that involves different regions of D1 [27]. In an international, multicenter evaluation, an 
association between anti-β2GPI-D1 antibodies and history of (mostly venous) thrombosis was 
found [28]. Recent studies have demonstrated that patients with multiple positive test results, usually 
considered at a higher risk of developing clinical complications, tend to have higher prevalence and 
higher titers of anti-β2GPI-D1 antibodies [29]. The hypothesis of antibodies specifically binding the 
domain I of the β2GPI molecule, as opposed to the whole molecule, as a promising biomarker with a 
better diagnostic accuracy when compared with current assays for anti-β2GPI is scientifically proven, 
although it needs to be evaluated further. 
Risk factors other than aPLs 
Recently, the role of vascular risk factors in the development of clinical events in patients with APS 
has been established. Patients with aPLs presenting with thrombosis frequently have one or more 
additional cardiovascular risk factors such as hypertension, smoking, hypercholesterolemia, or 
estrogen use [30]. 
When focusing on arterial events, Matyja-Bednarczyk et al. recently showed that livedo reticularis, as 
well as hypertension and hypercholesterolemia, increased the risk of arterial thrombosis in APS [31]. 
Moreover, the interaction between aPLs and smoking and oral contraceptives has been elucidated in a 
case-control study by Urbanus et al. [10] The authors showed that the risk of stroke doubled among 
LA-positive women who smoked, as compared with nonsmokers, and the risk of stroke among oral 
contraceptive users multiplied more than sevenfold. All LA-positive women who suffered a 
myocardial infarction were also smokers. 
Coexistent SLE may also have an impact on the risk of thrombosis as SLE is a risk factor for 
thrombosis per se. Patients with SLE have a higher-than-expected incidence of vascular events, which 
are not explained completely by traditional vascular risk factors[32]. The combination of SLE and 
aPLs is particularly a matter of concern, because aPL positivity has been shown to increase the risk of 
thrombosis in patients with SLE and a diagnosis of SLE appears to further enhance the likelihood of 
vascular events in patients with aPLs. Indeed, in aPL-positive SLE patients, the annual risk of first 
thrombosis is higher than in healthy aPL-positive subjects without other cardiovascular risks (4% vs. 
<1%) [33]. 
Observational studies suggest that manifestations of APS other than those included in the clinical 
classification criteria, such as heart valve lesions [11], livedo reticularis, and 
thrombocytopenia [30] may be associated with thrombosis; however, these associations are not 
considered strong enough to guide clinical decisions. 
The global APS score and mathematical approaches in risk stratification 
One of the unsolved questions is why some aPL carriers never develop any APS manifestation, some 
develop thrombosis while others present with morbidity during pregnancy and a small number of 
individuals develop a catastrophic form of APS. Therefore, assessing the risk of developing APS 
manifestations for an individual with aPLs is very important for physicians [37]. 
Three score models have been proposed to quantify the risk of thrombosis/obstetric events in 
APS [8], [38] and [39]. The main aim of these scores is to help clinicians stratify patients according to 
their risk, identifying those who have a higher likelihood of developing new events and therefore likely 
to benefit from preventive approaches. The first two scores [38] and [39] focused mainly on the aPL 
profile, while the most recent one, the Global APS Score or GAPSS [8], also included other variables 
such as cardiovascular risk factors and autoimmune profile at the time of implementation of the risk 
model (Table 3). 
This score has been internally and externally validated in different large prospective studies of patients 
with primary and secondary APS [40], [41] and [42]. GAPSS appears to be a promising tool in 
quantifying the risk of thrombosis and obstetric morbidity in patients with APS. 
Treatment 
Primary thromboprophylaxis 
It is still an open question whether prophylactic treatment is needed in subjects with aPLs who have no 
history of thrombosis. The net benefit of active therapy against placebo has never been clearly proven. 
However, we recommend a careful thrombotic risk assessment and general measures to control 
cardiovascular risk factors for all patients with aPLs as part of good clinical practice [43]. The 
avoidance of smoking and control of body weight, blood pressure, and lipids should be considered a 
primary management goal in all subjects with aPLs [8]. Estrogen-containing oral contraceptive pills or 
estrogen replacement therapy should be avoided due to their prothrombotic effect. 
Autoimmune conditions, mainly SLE, constitute an additional risk factor for thrombosis. Thus, 
primary thromboprophylaxis should be considered with LDA (75–100 mg/day) in all patients with an 
underling systemic autoimmune condition and persistent aPLs at medium–high titers (IgM or IgG 
phospholipid units >40 IgG phospholipid units (GPL) or IgM antiphospholipid units (MPL) or >99th 
percentile). In patients with SLE and with persistently positive aPLs, primary thromboprophylaxis 
including LDA and/or hydroxychloroquine (HCQ; 200–400 mg/day) is strongly recommended [43]. 
This is based on studies that have shown that HCQ protects against thrombosis in patients with SLE, 
including those with aPLs [11]. Although no study has specifically investigated whether the addition 
of anti-platelet agents offers additional protection, LDA is generally considered effective for primary 
thromboprophylaxis [43]. Thus, given the recommendation of HCQ therapy in all patients with SLE, 
the decision to add LDA should be determined on an individual basis. Specifically, the addition of 
LDA may be appropriate in selected cases, such as those with a high-risk aPL profile (e.g., triple 
positivity for LA, aCL, and anti-β2GPI, and/or other concomitant cardiovascular risk factors, and for 
SLE patients with a history of obstetric APS). 
However, while the Physicians' Health Study demonstrated no protection against deep venous 
thrombosis in men with aCL receiving LDA [44], more recent evidence suggests a protective role of 
LDA in venous thrombosis, at least in the general population [45]. 
In asymptomatic carriers of aPLs without an underlying connective tissue disease, the decision 
regarding thromboprophylaxis should be based on the aPL profile. LDA is suggested for those with a 
high-risk profile, such as patients with LA, and particularly for triple-positive individuals [41]. 
Recently, a prospective, multicenter, randomized, open, controlled trial conducted in patients positive 
for aPLs aimed to examine the efficacy and safety of LDA versus LDA plus low-intensity warfarin in 
the primary prevention of thrombosis in aPL-positive patients with SLE and/or obstetric 
morbidity [46]. No differences were observed in the number of thromboses between patients treated 
with LDA versus those treated with LDA + low-intensity warfarin. In the LDA + warfarin group, more 
episodes of bleeding were detected. The authors concluded that the LDA + warfarin regimen was 
significantly less safe than LDA alone. 
Prevention of recurrent thrombosis 
At present, the management of APS patients with a history of thrombosis is based on long-term 
antithrombotic therapy, due to the high rate of recurrent thrombosis (29% per year without 
treatment) [41]. Whether patients with APS should receive the same therapy as the general population 
with similar manifestations and whether arterial and venous events should be treated differently remain 
to be answered. 
Two randomized, controlled trials have compared high (target international normalized ratio, INR, 
3.0–4.0) with standard (target INR 2.0–3.0) intensity of anticoagulation for secondary 
thromboprophylaxis in patients with APS [47] and [48]. In these trials, no significant differences in 
terms of efficacy or safety between the regimens were observed. However, both suffered from bias due 
to overrepresentation of patients with their first VTE. Thus, we recommend indefinite anticoagulant 
therapy with a vitamin K antagonist (VKA) to a target INR of 2.0–3.0 for patients with APS and the 
first venous event. A reduction in the duration of treatment with VKA can be considered only in 
patients with a low-risk aPL profile and clear provoking factors (e.g., surgery and prolonged 
immobilization) at the time of the thrombosis. 
Instead, management of arterial events is more controversial and debate persists [49]. The APS and 
Stroke Study concluded that patients with stroke and aPL not fulfilling classification criteria should be 
best treated as the general population, with low-dose aspirin [50]. However, at present we use a more 
aggressive approach for patients with definite APS with arterial disease and/or recurrent events, which 
might include VKA with a target INR of 3.0–4.0. Occasionally, combined anticoagulant–antiaggregant 
therapy may also be considered [41]. In fact, recurrences are very infrequent (0.016–0.031 events per 
patient per year) among patients receiving effective oral anticoagulation targeting an INR of 3.0–
4.0 [51]. However, the physician has to be aware that high-intensity oral anticoagulation therapy 
carries a risk of serious hemorrhage, although this risk does not appear higher than that observed in 
other thrombotic conditions warranting oral anticoagulation [52]. 
However, the management of VTE is changing rapidly as the new direct oral anticoagulants (DOACs) 
have been shown to be effective in the management of VTE and they do not require laboratory 
monitoring [53]. A direct thrombin inhibitor (dabigatran etexilate) and direct anti-Xa inhibitors 
(rivaroxaban, apixaban, and edoxaban) are currently available. The use of these agents may represent a 
major step forward as, unlike VKA, they have few reported drug interactions and they do not interact 
with food or alcohol intake, thereby resulting in more stable anticoagulant intensity. Early evidence for 
the use of DOACs for secondary thromboprophylaxis for APS patients with a history of VTE is 
promising, but until data from ongoing clinical trials are available [53], there is not enough evidence to 
use DOACs in patients with APS and a history of arterial events. However, it is worth noting that LA 
testing in patients receiving DOACs may be unreliable [53]. 
Alternative therapies for refractory and difficult cases 
Long-term management of APS patients with recurrent thrombosis may be complicated by fluctuating 
INR levels, major bleeding, or a high risk of major bleeding. For these reasons, further therapeutic 
options other than VKA might be considered in selected cases. 
Long-term low-molecular-weight heparin (LMWH; e.g., subcutaneous enoxaparin 1 mg/kg every 12 h 
or 1.5 mg/kg/day or subcutaneous dalteparin 100 IU/kg every 12 h or 200 IU/kg/day), HCQ (200–
400 mg/day), or statins have been suggested in these selected cases [54]. 
Recently, rituximab, an anti-CD20 monoclonal antibody, has been shown to be effective in life-
threatening catastrophic APS, although it has been investigated in a small number of cases [54]. B-cell 
depletion with rituximab may also be used successfully in patients with aPLs and autoimmune-
mediated thrombocytopenia and hemolytic anemia [54]. A pilot open-label phase II trial of B-cell 
depletion with rituximab for non-criteria manifestations of APS concluded that rituximab may 
represent a safe option in APS especially in the case of thrombocytopenia or skin ulcers, although it 
may not be effective for all non-criteria manifestations (e.g., cardiac valve disease and aPL 
nephropathy) [55]. 
There is limited evidence for the use of steroids, other immunosuppressive drugs, or intravenous 
immunoglobulin (IVIg) in the treatment of APS patients with thrombosis [54]. These drugs should be 
considered only as rescue therapy in patients with repeated episodes of thrombosis despite adequate 
anticoagulant therapy, or in catastrophic APS. Anecdotal cases of the use of eculizumab, which targets 
the complement protein C5, have also been reported [54]. 
Other options can be considered on an individual basis, such as the use of intra-arterial fibrinolysis in 
patients with acute myocardial infarction associated with APS or prostacyclin analogs in patients with 
severe ischemic necrotic toes associated with APS. 
Newer therapeutic agents targeting pathways involved in the development of aPL-mediated clinical 
manifestations are under investigation. These include blocking of aPL/β2GPI receptors on target cells, 
complement and nuclear factor-κB, and P38 mitogen-activated kinase inhibitors. However, the 
multifactorial mechanisms underlying thrombosis and pregnancy morbidity in APS are still not fully 
understood and this might limit the development of new targeted therapies for APS. Potentially, the 
current “antithrombotic” approach to APS patients will be replaced in the future by an 
“immunomodulatory” approach as our understanding of the mechanisms of aPL-mediated clinical 
manifestations improves [55]. 
Obstetrical APS 
Pathogenesis 
The pathogenic role of aPLs in obstetrical APS (OAPS) was initially demonstrated by experimental 
models showing that the passive transfer of IgG isotype aPLs could induce FD and IUGR in pregnant 
mice [56]. Three mechanisms for aPL-induced pregnancy morbidity have been postulated: 
intraplacental thrombosis, defective placentation, and inflammation. 
Intraplacental thrombosis and the subsequent alteration of maternal–fetal blood exchanges were 
thought to be the main pathogenic mechanism of OAPS for many years. This was based on the 
frequent observation of thrombosis and infarction in histological studies of placentas from APS 
patients and in vitro studies, suggesting that anti-β2GPI antibodies displace the anticoagulant A5 from 
the trophoblast and endothelial cell monolayers [57]. Nevertheless, placentas from APS patients do not 
always show evidence of thrombosis and also display inflammatory changes [58]. Moreover, 
intraplacental thrombosis is not likely to cause early pregnancy losses, based on the fact that 
significant maternal blood flow is not present in the intervillous space until the end of the first 
trimester[59]. 
Based on the ability of anti-β2GPI to react with both the fetal and the maternal sides of the placenta 
in vitro, a role for aPLs in inducing defective placentation has emerged [60]. In particular, aPLs have 
been demonstrated to induce direct placental damage by inhibiting trophoblast differentiation and 
syncytialization, inducing trophoblast apoptosis, impairing trophoblast invasiveness, affecting 
trophoblast expression of adhesion molecules that regulate its adhesion to and invasion of the maternal 
tissue, and by inhibiting production of angiogenic factor by trophoblasts [59]. The internalization of 
aPLs by trophoblasts with the subsequent acceleration of cell death and release of debris that can 
activate maternal endothelial cells has been proposed as an additional mechanism for PreE [61]. 
Inflammation has been described as one of the main mechanisms of aPL-induced pregnancy morbidity 
based on (a) the histological demonstration of complement deposition, neutrophil infiltration, and 
tumor necrosis factor α secretion in decidual tissue; (b) the observation that complement deficiency in 
animal models or complement inhibition in vivo are protective against obstetrical complications; (c) 
the evidence of a protective effect of heparin linked to its anticomplement activity; and (d) the 
observation in in vitro studies that aPLs can induce trophoblasts to produce interleukin-1β by 
inflammasome activation ∗[62] and [63]. 
Although the pathogenic mechanisms of pregnancy morbidity have been increasingly proposed in the 
past years, research efforts to identify the aPL targets on cell membranes and the intracellular signaling 
pathways are still ongoing [62]. Heparan sulfate, Toll-like receptors 2 and 4, apolipoprotein E receptor 
2, and annexin II that are expressed by trophoblasts and decidual cells are the main candidate receptors 
for β2GPI identified by in vitro studies [62]. In particular, apolipoprotein E receptor 2 has been 
suggested to be the key molecule mediating trophoblast dysfunction in a mouse model [64], and Toll-
like receptor 4 has been demonstrated to mediate the in vitro inhibition of trophoblast invasion induced 
by purified aPL IgG from patients with OAPS but not by aPL IgG from non-OAPS[65]. 
Diagnosis 
Association between aPLs and clinical events 
The association between different obstetrical events and aPLs has been studied with contrasting results 
that have been critically reviewed by a Task Force comprising international experts during the 14th 
International Congress on aPLs [66]. In particular, even if the majority of numerous studies report a 
positive association between aPLs and REPL, they were affected by significant methodological 
heterogeneity with only very few studies meeting the classification criteria. The experts concluded that 
few studies support an association between aPLs and REPL. Similarly, FD, the first obstetrical 
complication associated with aPLs that is considered to be the most specific feature of OAPS, was 
associated with aPLs in few studies including a systematic literature review [67] and a large 
prospective population-based study [68]. The literature concerning the relationship between aPLs and 
PreE and placental insufficiency (PI) is even more tenuous (case-control studies and cohort studies, 
respectively, in the majority of cases) [66]. A critical review of the literature on an association of aPLs 
with clinical manifestations found that the differences in the frequencies of aPLs between patients and 
controls were significant for overall pregnancy morbidity, pregnancy loss, FD, and severe PreE but not 
for REPL, IUGR, PreE, eclampsia, and HELLP syndrome [69]. In summary, multicenter studies using 
classification criteria for inclusion are needed to confirm the association between aPLs and obstetrical 
morbidity [66]. The standardization of aPL tests between centers is critical. Independent laboratories, 
as those created by the APS action network [70], could have a significant role in confirming positive 
tests. 
aPLs, not included in the classification criteria, such as anti-phosphatidylethanolamine, aPT, aPT/PS, 
anti-phosphatidylinositol (aPI), and anti-A5, have been proposed to play a role in OAPS based on the 
observation of a higher prevalence in women with pregnancy morbidity [71], [72] and [73]. The Task 
Force on laboratory diagnostic and trends of the 14th International Congress on aPLs concluded that 
aPS and aPI may identify additional women with REPL [74], but that there is insufficient evidence to 
recommend routine testing for non-criteria antibodies at this time. 
Risk stratification 
Another matter of debate is the stratification of risk for pregnancy morbidity in aPL-positive patients. 
Historically, aPL titers have been considered important in this context and patients with high titers 
have been identified as those with higher risk of events. According to the classification criteria, only 
women with pregnancy morbidity and medium–high-titer aPLs should be diagnosed with OAPS. A 
pregnancy outcome similar to healthy controls was previously reported in women with low-titer aPLs 
supporting this hypothesis [75]. However, there is increasing evidence that such patients can 
experience poor pregnancy outcomes similarly to high-titer patients [76], [77] and [78]. These 
observations suggest that, in contrast to thrombotic events, low-titer aPLs can play a significant role in 
OAPS and that the actual classification criteria do not include all the OAPS cases. Among aPL 
specificities, LA and triple positivity have been identified as markers of worse 
outcome[79], ∗[80] and [69]. Finally, the presence of an associated systemic autoimmune disease, in 
particular SLE, a history of thrombotic events, and complement reduction have been recognized as 
being predictive of a poor pregnancy outcome [79] and [81]. Recently, the detection of altered 
angiogenic biomarkers in combination with clinical criteria during early gestation has been suggested 
as another tool predictive of adverse pregnancy outcome[82]. 
Instrumental tools 
Serial obstetrical ultrasonography to assess fetal growth/morphology and placental characteristics is an 
essential tool to identify pregnancy complications related to aPLs. Furthermore, uterine artery Doppler 
analysis during the second trimester has been used increasingly as a screening method to detect 
pregnancy complications associated with uteroplacental insufficiency, before the onset of clinical 
consequences [83]. Interest in earlier prediction of pregnancy morbidity has led to studies of the role of 
uterine artery Doppler analysis in the first trimester, which showed good accuracy for predicting early 
PreE and IUGR, particularly when combined with maternal characteristics and biochemical 
biomarkers [84]. New techniques including magnetic resonance imaging to detect PI and abnormal 
fetal brain development are under investigation as noninvasive screening methods to predict placental 
insufficiency-related complications [85]. 
Treatment 
Standard treatment 
The rate of successful pregnancy outcomes in APS patients without any treatment is very low (20–
30%), while with current treatment, APS patients have a 70–80% chance of a live birth [80]. Although 
controversial, due to a limited number of trials that mostly included patients who did not meet criteria, 
the current standard of care for pregnant patients fulfilling criteria for APS, based on international 
recommendations, consists of the following ∗[66] and ∗[86]. 
- 
LDA combined with prophylactic doses of unfractionated heparin or LMWH for patients 
fulfilling the APS classification criteria based on a history of pregnancy morbidity only; 
- 
LDA and therapeutic doses of unfractionated heparin or LMWH (switching from warfarin as 
soon as pregnancy is confirmed) for patients fulfilling the APS Classification Criteria based on 
a thrombotic event regardless of a history of pregnancy. 
The efficacy of heparin and LDA together in APS patients with previous pregnancy loss is supported 
by three meta-analyses [87], [88] and [89]. There is less evidence for the same approach in 
manifestations other than pregnancy loss. Furthermore, the common practice of using LMWH, instead 
of unfractionated heparin, is not supported by robust evidence, as only unfractionated heparin has 
shown a beneficial effect when added to LDA, whereas data on LMWH are inconclusive [66]. 
LDA has been shown not only to prevent placental thrombosis by its well-known anti-platelet effect 
but also to favor placental development by increasing interleukin-3 [90]. Heparin, beyond its 
anticoagulant effect, is able to prevent aPL binding to trophoblast, to antagonize the aPL-induced 
interference with trophoblast syncytialization, apoptosis, invasion, and hormonal production, to 
antagonize aPL-induced complement activation, to promote the cleavage of β2GPI, but also to block 
the aPL-mediated inhibition of endometrial endothelial cell angiogenic differentiation, to aid the 
clearance of pro-inflammatory chemokines, and to block inflammatory cell adhesion and migration 
through endothelial cells [59] and [91]. 
Treatment of refractory cases 
In patients failing LDA and heparin combination, although there are no evidence-based 
recommendations, common next steps used by physicians with experience in OAPS are as follows: 
increasing LMWH (from a prophylactic to a therapeutic dose) and/or adding one or more molecules 
among HCQ, low-dose corticosteroids, IVIg, and/or apheresis [92]. The use of such strategies could 
improve the obstetrical outcome, but the best regimen is yet to be identified. 
The rationale for HCQ is based on its ability, demonstrated in vitro, to reduce aPL binding to the 
trophoblast and to restore the expression of annexin 5 at the placental level [93]. The addition of HCQ 
to the standard therapy in refractory OAPS recently showed a reduction in pregnancy loss from 81% to 
19% in a retrospective multicenter study [80]. That result is supported by a retrospective single-center 
study on aPL-positive patients that showed that HCQ significantly increased the rate of live births 
(from 57% vs. 67%) and reduced the risk of any obstetrical complication [94]. The ability of HCQ to 
reduce aPL levels has been proposed as an additional mechanism of action in OAPS [95]. 
High-dose corticosteroids (e.g., prednisolone 40–60 mg/day) are associated with multiple 
complications during pregnancy (e.g., gestational diabetes, hypertensive disorders, and premature 
rupture of membranes). Nonetheless, based on the ability of steroids to impair complement activation 
both in vitro and in vivo [96] and the common practice in recent decades of using steroids in refractory 
cases, a group demonstrated that low-dose (10 mg) prednisolone during the first trimester was 
associated with an increased rate of live births in a small cohort [97]. 
Apheresis (plasma exchange or immunoadsorption), with the aim of removing aPLs from the maternal 
circulation, has been used in high-risk OAPS with success in some case series [98], [99] and [100] but 
evidence of a clear benefit is still lacking. 
IVIg has also been used in refractory OAPS based on its ability to inhibit the placental transport and to 
favor the clearance of maternal autoantibodies but also to modulate cytokine and complement 
activity [100] and [101]. Nevertheless, both a trial and a Cochrane meta-analysis failed to demonstrate 
any benefit of adding IVIg to standard treatment in improving the obstetrical outcome of 
OAPS [102] and [103]. 
Treatment of non-criteria patients 
No consensus exists for the treatment of non-criteria pregnant patients (low-titer aPLs or suggestive 
obstetrical history not fulfilling criteria), but most physicians, despite the lack of robust evidence, 
choose to treat these patients during pregnancy based on the presumption that such aPLs may be 
clinically relevant [104] and ∗[66]. Another matter of controversy is whether to treat asymptomatic 
aPL-positive patients (no history of vascular or pregnancy morbidity). A recent systematic review of 
the literature based on 154 pregnancies was not able to demonstrate superiority of prophylactic 
treatment with LDA over placebo in such aPL carriers [105]. A recent multicenter study of pregnant 
patients with confirmed aPL positivity showed that aPL carriers, despite prophylaxis in 100% of cases, 
had the same rate of adverse pregnancy outcome as OAPS (18%), but they were treated with 
combination regimen (LDA plus heparin) compared to OAPS less often [81]. 
New drugs 
New drugs for the treatment of OAPS have been studied in recent years. For example, TIFI, a synthetic 
peptide able to compete and to displace β2GPI molecule from the cell surface including the 
trophoblast, was able to prevent aPL-mediated fetal loss in mice. However, the observation that mice 
lacking β2GPI had an altered early pregnancy process led researchers to focus on molecules able to 
prevent aPL-mediated effects without changing the expression of β2GPI at placental 
level [106] and [107]. 
Future research agenda 
Despite advances in the understanding of APS in recent years, many areas need to be investigated 
further. Although it seems imperative to increase the efforts in determining optimal prognostic markers 
and therapeutic measures to prevent APS complications, difficulties in conducting randomized control 
trials in the setting of a relatively rare condition still remain. Well-designed longitudinal observational 
multicenter studies, such as prospective registries, using agreed classification criteria, validated 
outcome measures, and standardized laboratory tests should be performed to address the remaining 
questions. 
Recently, some large longitudinal studies have provided further insights on some open questions in the 
field of APS. Among others, investigators from the Predictors of Pregnancy Outcome: Biomarkers in 
APL Syndrome and SLE (PROMISSE) study group (ClinicalTrials.gov identifier NCT00198068) have 
shown that timely risk stratification of patients with aPLs is important for effective clinical care and 
optimal allocation of health-care resources [79] and [82]. PROMISSE is the largest multicenter, 
multiethnic, and multiracial study to prospectively assess clinical and laboratory predictors of adverse 
pregnancy outcome in SLE and/or aPL women with inactive or mild/moderate activity at conception. 
This study provided a basis for identifying high-risk patients for enrollment in future trials, and a 
rationale for investigating interventions that target pathways upstream (e.g., complement activation or 
TNF-α release) or downstream of antiangiogenic factors, sufficiently early to prevent pregnancy 
morbidity in APS. 
Given the rarity of OAPS, a homogeneous database in a multicenter European Registry where 
physicians could enter patient data was developed recently to facilitate and understand several gaps 
associated with aPL-related obstetric syndromes [80]. This study showed that the characteristics of 
OAPS differ from those of classical APS, that all laboratory test categories are needed to avoid false-
negative diagnoses, and that, in some cases, complement levels could act as a serological marker. 
Cervera et al. [108] recently assessed the prevalence of the main causes of morbidity and mortality in 
APS during a 10-year follow-up period, in one of the longest observational studies available in APS. 
They showed that patients with APS still develop significant morbidity (thrombotic events appeared in 
16.6% patients during the first five-year period and in 14.4% during the second five-year period) and 
mortality (the survival probability at 10 years was 90.7%) despite current treatment. 
Future studies are needed to confirm the association of aPL with clinical manifestations reported in the 
classification criteria and to clarify the role of non-criteria aPLs. They may also support the benefit of 
standard treatment, identify the best approach for refractory and incomplete cases of APS, and further 
assess the pleiotropic effects of agents such as statins and HCQ whose addition to anticoagulation may 
lead to better disease control. Finally, they could help to identify novel diagnostic tools, such as 
antibodies against DI of β2GPI or against PS/PT, which may allow more precise risk stratification, 
leading to a tailored treatment strategy. 
Summary 
There have been many advances in the understanding of APS in recent years, but many areas need to 
be further investigated in particular the association between autoantibodies and clinical manifestations, 
the identification of high-risk patients, the best treatment for each patient category, and the role of new 
therapeutic strategies. Well-designed longitudinal observational multicenter studies, such as 
prospective registries, using classification criteria, validated outcome measures, and standardized 
laboratory tests should be performed to answer the remaining questions. 
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Table 1. Revised classification criteria for antiphospholipid syndrome. 
Vascular 
thrombosis 
≥1 clinical episode of arterial, venous, or small vessel thrombosis. Thrombosis must be objectively 





≥1 unexplained death of a morphologically normal fetus ≥10 weeks of gestation 
2 
≥1 premature delivery of a morphologically normal fetus <34 weeks of gestation because of: 
• 
severe preeclampsia or eclampsia defined according to standard definition; 
• 
recognized features of placental insufficiency 
3 
≥ 3 unexplained consecutive miscarriages <10 weeks of gestation, with maternal and paternal 
factors (anatomic, hormonal, or chromosomal abnormalities) excluded 
Laboratory 
criteria 
Presence of antiphospholipid antibodies (aPL), on two or more occasions at least 12 weeks apart and no 
more than 5 years prior to clinical manifestations, as demonstrated by ≥1 of the following: 
a Lupus anticoagulant; 
b Medium to high-titer (>40 GPL or MPL, or >99th percentile) anticardiolipin IgG or IgM; 








Lupus anticoagulant positivity 
• 
Triple positivity (lupus anticoagulant + anti-cardiolipin + anti-β2 glycoprotein-I 
antibodies) 
• 
























The GAPSS scoring system is derived from the combination of independent risk for both thrombosis and pregnancy loss, 
and accounted for multiple factors, including the patient's aPL profile, conventional cardiovascular risk factors, 
autoimmune antibody profile, and thromboprophylactic drug use. The GAPSS can be calculated for each patient by adding 
the points corresponding to the different risk factors, weighted as shown. GAPSS values ≥10 have demonstrated the best 
diagnostic accuracy compared with the different thresholds for APS diagnosis. 
 
Factor Point value 
Anticardiolipin IgG/IgM 5 
Anti-β2-glycoprotein IgG/IgM 4 
Lupus anticoagulant 4 
Anti-prothrombin/phosphatidylserine complex (aPS/PT) IgG/IgM 3 
Hyperlipidemia 3 
Arterial hypertension 1 
